Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
A consortium of researchers identified a rare but important gene target, NRG1, responsible for development of various cancer types. The study suggests that targeting this gene fusion could effectively shut down cancers, offering a new therapy possibility.
Researchers combined CRISPR with drug discovery to understand how AML treatment works and which weaknesses can be exploited. The study revealed that LSD1-GFI1B relationship is critical for AML survival, enabling more targeted treatments.
Researchers have discovered that small molecule compounds can alter the spatial organization of the genome, potentially leading to new epigenetic cancer drugs. This breakthrough opens up a promising approach to treat cancer by changing the 3D genome structure.
Scientists successfully blocked cancer-fighting gene silencing protein UHRF1, restoring hundreds of protective genes in human colon cancer cells. The findings suggest a new strategy for fighting cancers by targeting this protein.
Researchers discovered that cancer cells can hide from immunotherapy by altering the levels of a key molecule on their surface. However, they identified an existing inhibitor of the WNT pathway that could potentially reverse this process and make cancer cells more visible to immune cells.
One-third of cancer patients use complementary and alternative medicines such as meditation, yoga, acupuncture, and herbal supplements. Many patients do not disclose their use to doctors due to lack of knowledge or perceived need for disclosure.
A nationwide survey found that 33.3% of cancer patients used complementary and alternative medicines, with herbal supplements being the most common. Many participants did not disclose their CAM use due to lack of physician inquiry or perceived unnecessary information.
Researchers at USC and UCLA have developed a new method to prevent damage to the jaw, a side effect of cancer treatment. The approach uses a different BP compound that can be used locally in the mouth to push the drug from the jawbone while leaving the useful drug undisturbed.
Researchers have identified chromogranin A as a key regulator of cardiotoxic and antitumor activities of Doxorubicin, a widely used cancer drug. Monitoring plasma levels of CgA before and after chemotherapy may provide prognostic information on drug-related cardiotoxicity.
Researchers used CRISPR technology to disrupt every gene in over 300 cancer models from 30 cancer types, discovering thousands of key genes essential for cancer's survival. The team developed a system to prioritize and rank 600 drug targets promising for development into targeted cancer treatments.
Cancer cells dependent on WRN enzyme to survive due to DNA repair system loss; MSI signature identified as effective biomarker for vulnerable tumors.
Researchers at UCSF have developed a new screening system to identify effective cancer-killers when combining drugs that are only partially effective as single-agent therapies. The study identified combinations of PI3K inhibitors and RNAi that eradicated a devastating blood cancer and certain solid tumor cells.
A comprehensive SWOG Cancer Research Network study has identified a host of targets for new or existing cancer drugs. The research, published in the Journal for ImmunoTherapy of Cancer, found higher counts of cancer-fighting TILs in pre-treatment tissue samples of breast cancer patients who achieved complete response to chemotherapy.
A recent study published in Nature Metabolism identified a novel pathway regulating drug tolerance in non-small-cell lung cancers with a specific mutation. MicroRNA miR-147b was found to mediate resistance to EGFR-based treatments, suggesting a potential new approach for treatment of lung cancer.
A USC study found that despite substantial media attention, most cancer drugs in shortage had little to no effect on chemotherapy treatment. Researchers analyzed over 2.4 million claims and found minimal change in treatment for the majority of oncology drugs during shortages.
A telerehabilitation program has been shown to improve the physical function, pain, and quality of life of patients with late-stage cancers. The study found that these patients who received remotely delivered rehabilitation services had fewer hospital and nursing home stays.
Researchers at Harvard Medical School and Dana-Farber Cancer Institute identify key molecules supporting lung cancer cell survival, demonstrating simultaneous inhibition of two signaling pathways. This approach could aid in designing drugs that selectively attack multiple proteins, beneficial for managing certain tumors.
A recent study in animal models of diffuse intrinsic pontine glioma (DIPG) has identified an experimental drug that effectively destroys DIPG cells by depleting cellular cholesterol. The researchers also found that the compound works by directly inhibiting lanosterol synthase, an enzyme involved in cholesterol production.
Researchers discovered that adiponectin, a hormone secreted by fat cells, protects female mice from liver cancer. In contrast, increased testosterone levels in male rodents reduce tumor growth and lower adiponectin levels.
Professor Jonas Bergh is recognized for his work on breast cancer biology, including tailored treatments and the impact of chemotherapy. He has made significant contributions to primary breast cancer treatment through his involvement in clinical trials and research collaborations.
Salk scientists discovered a new mechanism of action for the CDK12 protein, revealing its role in regulating gene expression and cell division. This finding suggests that targeting CDK12 could be an effective way to kill cancer cells and improve treatment outcomes.
Dr. Carl June receives the 2019 Harrington Prize for his contributions to CAR T therapy, a revolutionary cancer treatment. The prize honors his development of new strategies and culture systems that have enabled CAR T clinical trials.
A Phase II trial at MD Anderson Cancer Center showed umbralisib to be an effective treatment for patients with relapsed marginal zone lymphoma, achieving a 55% partial or complete response rate. The drug was well-tolerated, with a 71% progression-free survival after one year.
A new study by University of Pittsburgh researchers has identified a previously unknown mechanism used by tumors to suppress the immune system. The study found that tumors use two types of immune cells, regulatory T cells (Tregs), to release inhibitory cytokines, which activate a protein called BLIMP1 and disable killer T cells.
Early results from the UNITY-NHL phase II clinical trial show umbralisib to be highly active against relapsed/refractory marginal zone lymphoma, with a 55% partial or complete response rate and 71% progression-free survival at 12 months.
Researchers found that combining adavosertib with irinotecan, navitoclax or capecitabine increased its effectiveness against pancreatic cancer. The study aimed to identify new combinations of drugs to enhance adavosertib's effect.
Researchers found tarloxotinib effective against various cancer types, including ovarian and breast cancers with NRG1 gene fusions. The drug targets low-oxygen conditions, making it potentially more tolerable than existing therapies.
A University of Colorado Cancer Center study identifies a compound that inhibits the action of the SIX1/EYA transcriptional complex, which is involved in cancer metastasis. The compound dramatically suppresses breast cancer-associated metastasis in mouse models.
A combination of ipilimumab and nivolumab has been shown to shrink tumors in patients with high-grade neuroendocrine carcinoma by 42 percent, while all low-grade patients did not see a response.
Researchers found that the medicine DFMO not only blocks cell growth but also directly targets H. pylori to reduce its virulence. This could lead to a new strategy for preventing stomach cancer. The study supports further research into using DFMO to prevent stomach cancer.
Researchers have developed an experimental combined drug therapy that dramatically shrinks tumours and prevents metastasis in mice by targeting the DNA repair capability of cancer cells. The treatment has few side-effects compared to traditional chemotherapy and is being tested in clinical trials.
A national survey found that 81% of hospital pharmacy managers experienced medication hoarding due to drug shortages, with over two-thirds reporting more than 50 shortages. The survey highlights the need for more systematic approaches to address the issue and decrease rationing.
Researchers at Sanford Burnham Prebys have created a mouse model of choroid plexus carcinoma (CPC), a challenging type of brain cancer that affects young children. The study identified three promising drug compounds with biological activity, including dinaciclib and flavopiridol.
Researchers at Johns Hopkins Medicine have developed a new technique using PET scans to track the interaction between cancer drugs and tumor cells, providing valuable insights into how effective treatment is. This breakthrough could streamline cancer therapy by enabling doctors to tailor treatments, determine therapeutic doses, and avo...
Researchers will compare DNA from sepsis patients who died and survived to isolate signals and identify future drug targets. The study, funded by Sepsis Research, aims to better understand how genes govern sepsis recovery.
Researchers identified a critical protein for tumor cell survival and found that targeting it could be a novel treatment strategy for MSI-H tumors. The study suggests that pharmacological inhibition of WRN function might serve as a targeted therapeutic approach.
A new study finds that preventive medications, such as those for blood pressure and bone health, are frequently continued until death in older adults with cancer. The use of these medications can increase the risk of serious side effects and reduce quality of life.
A new study found that replacing a half hour of sitting time with light physical activity was associated with a nearly 50% reduction in mortality among the least active participants. Replacing sedentary time with moderate-intensity physical activity was also linked to a lower risk of death, although the association was smaller.
Researchers found that mda-7/IL-24 reduces the expression of an enzyme called DICER, which processes microRNAs for specific cellular functions. This effect occurs only in cancer cells and provides potential therapeutic targets for cancer treatment.
Researchers say gene interactions are key to understanding disease risk and treatment response, but current methods lack statistical power to uncover multiple genes. Genome-wide association studies have identified thousands of mutations that contribute to disease, but environmental effects and genetic diversity complicate matters.
Researchers have found that modulating blood-forming stem cells' stiffness could help drive them out of the bone marrow and into the blood, but they need to be stiff to stay put. The study, published in Cell Stem Cell, suggests that altering cell biomechanics can improve mobilization regimens for stem cell-based therapy.
Researchers at City of Hope have been awarded $7.5 million to develop new treatments for CTCL, a disfiguring and incurable cancer affecting about 3,000 individuals annually. The grant will support the development of personalized medicine and immunotherapy treatments.
The collaboration identifies leadership, patient engagement, and community engagement as crucial factors in increasing accrual of racial and ethnic minorities in cancer trials. High-recruiting centers like Henry Ford Cancer Institute excel in engaging providers, building trust, and seeking input from minority patients and caregivers.
Researchers found that cancer cells with fewer mitochondria are more likely to respond to certain drug treatments, offering a new avenue for targeted therapies. The study's findings suggest that enhancing understanding of the relationship between mitochondrial variability and drug response may lead to more effective cancer treatments.
Researchers at Oregon State University have patented a method for synthesizing cephalotaxine and homoharringtonine (HHT), previously only available from an Asian tree. This development paves the way for more readily available and affordable leukemia treatments.
Researchers have identified a promising new therapeutic strategy using two types of drug inhibitors to treat pancreatic cancer. The approach combines chloroquine with an inhibitor of the replication stress response pathway, showing potential in reducing tumor growth and improving prognosis.
Researchers at University of Alabama at Birmingham discovered androgen receptor imports into mitochondria, where it regulates multiple mitochondrial processes. This finding may lead to new treatment targets for castration-resistant prostate cancer.
Scientists at the University of Wisconsin-Madison have discovered an unexpected regulator of the p53 protein, which plays a crucial role in cancer development. The research team found that an enzyme called PIPK1-alpha and its lipid messenger, PIP2, drive the stability of mutant p53, leading to cancer progression.
Research has led to increased understanding of genetic changes in cancer, highlighting the potential for personalized care in children with cancer. Genetic profiling can inform prognosis and treatment decisions, providing critical information about tumor progression and response.
Researchers at Stanford University School of Medicine have discovered a method to forecast which breast cancer patients will experience heart problems from trastuzumab, a commonly used chemotherapy drug. A class of medications already approved by the FDA may mitigate these side effects.
A new study shows that innovative communication programs can improve patients' mental health symptoms and quality of life. The program, which involves structured conversations between clinicians and patients, results in more timely and meaningful discussions about patient values and goals.
A study from MIT and Brigham and Women's Hospital found that nearly all pills and capsules contain ingredients that can cause allergic reactions or irritations in certain patients. The researchers aim to raise awareness of this issue and stimulate reforms to protect patients.
Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a distinct form of cancer linked to textured breast implants. Clear guidelines formalize treatment strategy, recommending surgical techniques like stepwise en bloc resection for complete oncologic resection and removal of involved lymph nodes.
A nationally representative study found that teenagers and young adults are more likely to use fruit- and candy-flavored e-cigarettes than their adult counterparts. The study also revealed that adolescent vapers were more likely to experiment with multiple flavor types, which may be a key factor in their vaping habits.
A new experimental drug, 673A, targets and annihilates stem-like ovarian cancer cells that cause recurrence. The treatment, combined with chemotherapy, resulted in significantly greater survival rates in a mouse model of ovarian cancer.
A team of scientists has discovered a unique genetic signature, or 'fingerprint', in cancer cells that can be targeted to selectively eliminate abnormal cells. This breakthrough could lead to more effective and less toxic cancer treatments.
PARP inhibitors have been found to enhance the immune response against cancer cells with DNA repair defects, suggesting a new approach to treating various types of cancer. This discovery could lead to increased effectiveness of immunotherapies and improved treatment outcomes for patients.
A study found that rural areas have higher levels of ambiguity and fatalism regarding cancer, which can discourage participation in screenings. Researchers hope to develop customized interventions based on community needs and values.
Researchers have discovered a potential treatment for cancer in patients with epidermolysis bullosa, a severe skin disease also known as butterfly disease. The new drug, rigosertib, was shown to be highly effective at killing cancer cells in preclinical studies and may target the cancer without harming healthy cells.
Researchers at Bar-Ilan University discovered the intricate molecular mechanism of the guidance receptor 'Robo', which reacts to signals in its environment while avoiding premature activity. The findings provide a basis for designing effective drugs targeting Robo receptors, potentially treating various neurological and cancer conditions.